{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:51:36Z","timestamp":1791496296449,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.mcp.2026.102071","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:37:51Z","timestamp":1779464271000},"page":"102071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["First experiences in a US clinical laboratory with Oncomine Dx Express Test: Evaluation in formalin-fixed paraffin-embedded tissues"],"prefix":"10.1016","volume":"88","author":[{"given":"Amanda","family":"Weaver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Diercks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Sowada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Cotten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"D'Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinu","family":"Rill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Longshore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisa","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden","family":"Tomazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-2552","authenticated-orcid":false,"given":"Gary A.","family":"Pestano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.mcp.2026.102071_bib1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.mcp.2026.102071_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10520295.2018.1446101","article-title":"Factors that drive the increasing use of FFPE tissue in basic and translational cancer research","volume":"93","author":"Gaffney","year":"2018","journal-title":"Biotech. Histochem."},{"issue":"7","key":"10.1016\/j.mcp.2026.102071_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.mcp.2026.102071_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/life14111358","article-title":"Companion diagnostics (CDx) based on molecular biology techniques","volume":"14","author":"Kang","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.mcp.2026.102071_bib5","series-title":"List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) [Internet]","year":"2026"},{"issue":"10","key":"10.1016\/j.mcp.2026.102071_bib6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3390\/genes12101472","article-title":"Formalin-fixed and paraffin-embedded samples for next generation sequencing: problems and solutions","volume":"12","author":"Cazzato","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.mcp.2026.102071_bib7","series-title":"Oncomine DxTM Express Test P240040 Approval Letter, July 02, 2025 [Internet]","author":"Ghosh","year":"2025"},{"key":"10.1016\/j.mcp.2026.102071_bib8","article-title":"U.S. food and drug administration [Internet]","year":"2025","journal-title":"FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations"},{"key":"10.1016\/j.mcp.2026.102071_bib9","series-title":"PMA P240040: Summary of Safety and Effectiveness Data [Internet]","year":"2025"},{"key":"10.1016\/j.mcp.2026.102071_bib10","article-title":"Discovery launches SpecimenSeqTM","author":"Vanderwill","year":"2020","journal-title":"Discovery Life Sciences [Internet]"},{"key":"10.1016\/j.mcp.2026.102071_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113540","article-title":"Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies","volume":"200","author":"Zaun","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.mcp.2026.102071_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/diagnostics12030729","article-title":"Analytic and clinical validation of a pan-cancer NGS liquid biopsy test for the detection of copy number amplifications, fusions and exon skipping variants","volume":"12","author":"Audetat","year":"2022","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.mcp.2026.102071_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/diagnostics11020155","article-title":"Targeted next-generation sequencing of liquid biopsy samples from patients with NSCLC","volume":"11","author":"Mellert","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2026.102071_bib16","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1538-7445.AM2025-5886","article-title":"Cross-test performance verification of tissue-TMB and a cfDNA somatic variant next Generation Sequencing (NGS) panel for detection of actionable mutations","volume":"85","author":"Jackson","year":"2025","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.mcp.2026.102071_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmoldx.2016.11.004","article-title":"Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non\u2013small cell lung carcinoma","volume":"19","author":"Mellert","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.mcp.2026.102071_bib18","series-title":"PMA P240040: Labeling 2 [Internet]","year":"2024"},{"issue":"3","key":"10.1016\/j.mcp.2026.102071_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00314","article-title":"Weighing the evidence: variant classification and interpretation in precision oncology, US food and drug administration public workshop\u2014workshop proceedings","author":"Horne","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.mcp.2026.102071_bib20","series-title":"All Common Checklist. Northfield, IL","year":"2024"},{"key":"10.1016\/j.mcp.2026.102071_bib21","series-title":"StatPearls [Internet]","article-title":"TNM classification","author":"Rosen","year":"2026"},{"key":"10.1016\/j.mcp.2026.102071_bib22","article-title":"Optimization for sequencing and analysis of degraded FFPE-RNA samples","volume":"160","author":"Levin","year":"2020","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.mcp.2026.102071_bib23","series-title":"Molecular Pathology Checklist [Internet]","year":"2025"},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12864-018-4544-x","article-title":"Analytical parameters and validation of homopolymer detection in a pyrosequencing-based next generation sequencing system","volume":"19","author":"Iv\u00e1dy","year":"2018","journal-title":"BMC Genom."},{"issue":"2","key":"10.1016\/j.mcp.2026.102071_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jalm\/jfaf183","article-title":"Precision profile weighted deming regression for methods comparison","volume":"11","author":"Hawkins","year":"2026","journal-title":"J. Appl. Lab. Med."},{"issue":"3","key":"10.1016\/j.mcp.2026.102071_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/labmed-2013-0003","volume":"37","author":"Haeckel","year":"2013","journal-title":"LaboratoriumsMedizin"},{"key":"10.1016\/j.mcp.2026.102071_bib27","series-title":"R: a Language and Environment for Statistical Computing","year":"2025"},{"key":"10.1016\/j.mcp.2026.102071_bib28","author":"Carstensen"},{"issue":"4","key":"10.1016\/j.mcp.2026.102071_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jmoldx.2024.01.005","article-title":"Next-generation sequencing trends among adult patients with select advanced tumor types: a real-world evidence evaluation","volume":"26","author":"Ferreira-Gonzalez","year":"2024","journal-title":"J. Mol. Diagn."},{"issue":"11","key":"10.1016\/j.mcp.2026.102071_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jalm\/jfad091","article-title":"Clinical utility and benefits of comprehensive genomic profiling in cancer","volume":"9","author":"Tjota","year":"2024","journal-title":"J. Appl. Lab. Med."},{"issue":"9","key":"10.1016\/j.mcp.2026.102071_bib32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of hybridization capture versus amplicon\u2010based methods for whole\u2010exome sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13010042","article-title":"Assessment of two commercial comprehensive gene panels for personalized cancer treatment","volume":"13","author":"Ottestad","year":"2022","journal-title":"J. Personalized Med."},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99933-2","article-title":"Evaluation of a custom QIAseq targeted DNA panel with 164 ancestry informative markers sequenced with the illumina MiSeq","volume":"11","author":"Truelsen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcp.2026.102071_bib35","series-title":"PMA P240040: Labeling [Internet]","year":"2024"},{"key":"10.1016\/j.mcp.2026.102071_bib36","author":"Hendriks"},{"issue":"4","key":"10.1016\/j.mcp.2026.102071_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcp.2026.102071_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105740","article-title":"164P ProTarget study: investigating BRAF-targeted therapies in cancers beyond melanoma and colorectal cancer","volume":"10","author":"Belcaid","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.mcp.2026.102071_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13073-019-0691-1","article-title":"Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank","volume":"12","author":"Abul-Husn","year":"2019","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-020-00744-3","article-title":"Ancestry-specific predisposing germline variants in cancer","volume":"12","author":"Oak","year":"2020","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/ol.2023.13868","article-title":"Germline EGFR mutations in lung cancer","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mcp.2026.102071_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104626","article-title":"Next-generation sequencing for PTEN testing in HR+\/HER2\u02d7 metastatic breast cancer","volume":"207","author":"Fusco","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"22","key":"10.1016\/j.mcp.2026.102071_bib50","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.mcp.2026.102071_bib51","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"19","key":"10.1016\/j.mcp.2026.102071_bib52","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1158\/1078-0432.CCR-21-1115","article-title":"A phase I, open-label, dose-finding study of GSK2636771, a PI3K\u03b2 inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"27","author":"Sarker","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.mcp.2026.102071_bib53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing\u2013based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"4","key":"10.1016\/j.mcp.2026.102071_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289188","article-title":"Performance of amplicon and capture based next-generation sequencing approaches for the epidemiological surveillance of Omicron SARS-CoV-2 and other variants of concern","volume":"19","author":"Davi\u00f1a-N\u00fa\u00f1ez","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2026.102071_bib55","series-title":"PMA P170019: Summary of Safety and Effectiveness Data [Internet]","year":"2017"},{"issue":"4","key":"10.1016\/j.mcp.2026.102071_bib57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jmoldx.2025.01.002","article-title":"Clinical validation of the TruSight oncology 500 assay for the detection and reporting of pan-cancer biomarkers","volume":"27","author":"Al-Kateb","year":"2025","journal-title":"J. Mol. Diagn."},{"issue":"24","key":"10.1016\/j.mcp.2026.102071_bib59","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2026.102071_bib60","doi-asserted-by":"crossref","first-page":"642","DOI":"10.18632\/oncotarget.28761","article-title":"Clinical and analytical validation of MI cancer seek\u00ae, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay","volume":"16","author":"Domenyuk","year":"2025","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.mcp.2026.102071_bib61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmoldx.2019.03.005","article-title":"Fixation effects on variant calling in a clinical resequencing panel","volume":"21","author":"Parker","year":"2019","journal-title":"J. Mol. Diagn."},{"issue":"14","key":"10.1016\/j.mcp.2026.102071_bib62","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1093\/nar\/gkad519","article-title":"A critical spotlight on the paradigms of FFPE-DNA sequencing","volume":"51","author":"Steiert","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"10.1016\/j.mcp.2026.102071_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132429","article-title":"Deconstructing intratumoral heterogeneity through multiomic and multiscale analysis of serial sections","volume":"16","author":"Schupp","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.mcp.2026.102071_bib64","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcp.2026.102071_bib65","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1186\/s12885-024-13163-z","article-title":"MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study","volume":"24","author":"Cai","year":"2024","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.mcp.2026.102071_bib66","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2025.06.011","article-title":"Two paths: amivantamab: a promising treatment for NSCLC with Exon 14 skipping mutations of MET","volume":"20","author":"Murata","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.mcp.2026.102071_bib67","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/1078-0432.CCR-25-1247","article-title":"Crizotinib in patients with tumors with MET amplification or exon 14 deletion: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2","volume":"32","author":"Coleman","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.mcp.2026.102071_bib68","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cancers14092223","article-title":"Copy number alterations as novel biomarkers and therapeutic targets in colorectal cancer","volume":"14","author":"Tan","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.mcp.2026.102071_bib69","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mcp.2026.102071_bib70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.18632\/oncotarget.28188","article-title":"Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers","volume":"13","author":"Shah","year":"2022","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.mcp.2026.102071_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105561","article-title":"FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling","volume":"10","author":"Lyu","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.mcp.2026.102071_bib72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2017.11.003","article-title":"Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the association for molecular pathology and the college of American pathologists","volume":"20","author":"Roy","year":"2018","journal-title":"J. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.mcp.2026.102071_bib73","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic profiling of advanced non\u2013small cell lung cancer in community settings: gaps and opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.mcp.2026.102071_bib74","volume":"A","year":"2025"},{"key":"10.1016\/j.mcp.2026.102071_bib75","article-title":"Functional characterization and a real-world clinical laboratory pilot of the foundation for the national institutes of health circulating tumor DNA quality control materials","volume":"9","author":"Paweletz","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"18","key":"10.1016\/j.mcp.2026.102071_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813788","article-title":"European real-world assessment of the clinical validity of a CE-IVD panel for ultra-fast next-generation sequencing in solid tumors","volume":"24","author":"Normanno","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850826000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850826000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T07:59:42Z","timestamp":1783238382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850826000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S0890850826000113"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2026.102071","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First experiences in a US clinical laboratory with Oncomine Dx Express Test: Evaluation in formalin-fixed paraffin-embedded tissues","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2026.102071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102071"}}